Bulevirtide

Source high-purity Bulevirtide (Hepcludex), a first-in-class entry inhibitor peptide for advanced virology and hepatology research. This synthetic lipopeptide effectively blocks NTCP receptors, preventing Hepatitis B and D virus entry into hepatocytes. Ideal for laboratories studying viral pathogenesis and developing novel antiviral therapies. High-quality raw material. Get a quote today!

Product Specification

• Product Name: Bulevirtide (Research Grade)
• Appearance: White to off-white lyophilized powder
• CAS No.: 1530796-82-8
• Molecular Formula: C₁₇₅H₂₈₉N₄₇O₄₆S (Myristoylated peptide)
• Specification: Purity ≥98% (HPLC); Molecular Weight: ~4056.6 g/mol; Endotoxin <1.0 EU/mg
• Ingredient Information: Synthetic 47-amino acid lipopeptide derived from PreS1 domain of HBV; N-myristoylated at N-terminus

Product Description

Bulevirtide is a groundbreaking synthetic lipopeptide that acts as a first-in-class entry inhibitor for Hepatitis B (HBV) and Hepatitis D (HDV) viruses. By specifically binding to the Sodium Taurocholate Co-transporting Polypeptide (NTCP) receptor on hepatocytes, it prevents viral attachment and entry, effectively halting infection spread. Its unique mechanism offers a distinct advantage over traditional nucleos(t)ide analogs, targeting the initial stage of the viral life cycle. As the demand for functional cures for chronic hepatitis grows, Bulevirtide stands out for its potent antiviral activity and favorable safety profile in preclinical and clinical studies. It is an essential tool for researchers exploring novel therapeutic strategies against hepadnaviruses and delta viruses.

Product Uses

This ingredient is strictly intended for laboratory research and preclinical development. It is widely used in virology research to investigate the mechanisms of HBV and HDV entry into liver cells. Scientists utilize Bulevirtide in cell-based assays using NTCP-expressing hepatocytes to evaluate viral inhibition kinetics and receptor binding affinity. Additionally, it serves as a critical reference standard in drug discovery programs aimed at developing next-generation entry inhibitors. It is also employed in animal models of chronic hepatitis to study the effects of viral suppression on liver pathology and immune response. It is not approved for human consumption outside of regulated clinical trials.

Formulation Recommendation

Reconstitution: Dissolve in sterile deionized water or PBS containing 0.1% BSA to prevent adsorption. Gentle vortexing is recommended. Final concentration typically 1–5 mg/mL. Aliquot and store at -80°C.
Usage Concentration: In vitro, effective concentrations range from 10 nM to 1 μM depending on cell line and viral strain. In vivo, dosing varies by model but often ranges from 1–10 mg/kg subcutaneously.
Compatibility: Compatible with standard cell culture media. Avoid freeze-thaw cycles. The myristoyl group enhances membrane affinity, so ensure proper solubilization. Synergizes well with nucleos(t)ide analogs in combination therapy studies.